Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4632.2012.05721.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Variant of Serpentine Supravenous Hyperpigmentation Following Subcutaneous Bortezomib Injection.
HCA Healthc J Med
December 2024
University of North Texas Health Science Center at Fort Worth, Fort Worth, TX.
Introduction: Bortezomib is a reversible proteasome inhibitor that is a first-line chemotherapeutic agent for multiple myeloma. Bortezomib can be administered intravenously or subcutaneously with similar efficacy. Subcutaneous administration has fewer side effects.
View Article and Find Full Text PDFBackground: Serpentine supravenous hyperpigmentation (SSH) is known as a phenomenon occurring during the infusion of chemotherapy agents in the underlying veins. Chemotherapy agents have potential to cause infusion reactions when used systematically. Linear hyperpigmentation and reticular hyperpigmentation are the differential diagnosis for this phenomenon.
View Article and Find Full Text PDFSerpentine supravenous hyperpigmentation in association with anti-TIF1-gamma antibody-positive myositis.
Int J Dermatol
February 2025
Ronald O. Perelman Department of Dermatology, New York University Langone Health, New York, NY, USA.
Transient Serpentine Supravenous Erythema During Rapid Drug Desensitization.
J Allergy Clin Immunol Pract
November 2024
Allergy and Immunology Division, Department of Medicine, Montefiore Medical Center, Bronx, NY. Electronic address:
Serpentine supravenous hyperpigmentation: a rare clinical image.
Pan Afr Med J
August 2024
Department of Respiratory Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Sawangi (Meghe), Wardha, Maharashtra, India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!